Vir Biotechnology, Inc. (NASDAQ:VIR) Director Sells $137,219.20 in Stock

Vir Biotechnology, Inc. (NASDAQ:VIR) Director Vicki L. Sato sold 10,960 shares of the firm’s stock in a transaction that occurred on Wednesday, January 8th. The shares were sold at an average price of $12.52, for a total transaction of $137,219.20. Following the completion of the sale, the director now directly owns 1,312,391 shares in the company, valued at approximately $16,431,135.32. This trade represents a 0.83 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Vir Biotechnology Trading Up 58.2 %

Shares of Vir Biotechnology stock traded up $4.59 on Wednesday, hitting $12.48. The stock had a trading volume of 39,456,292 shares, compared to its average volume of 8,750,732. The stock has a market cap of $1.72 billion, a price-to-earnings ratio of -3.18 and a beta of 0.51. Vir Biotechnology, Inc. has a 52-week low of $6.56 and a 52-week high of $14.45. The company’s 50 day moving average price is $8.08 and its 200 day moving average price is $8.31.

Vir Biotechnology (NASDAQ:VIR) last issued its quarterly earnings data on Thursday, October 31st. The company reported ($1.56) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.05) by ($0.51). The firm had revenue of $2.38 million during the quarter, compared to analysts’ expectations of $5.54 million. Vir Biotechnology had a negative net margin of 678.40% and a negative return on equity of 36.71%. Vir Biotechnology’s quarterly revenue was down 9.8% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($1.22) EPS. Analysts predict that Vir Biotechnology, Inc. will post -3.36 EPS for the current fiscal year.

Institutional Trading of Vir Biotechnology

A number of large investors have recently bought and sold shares of the business. Bank of New York Mellon Corp raised its stake in shares of Vir Biotechnology by 0.8% during the second quarter. Bank of New York Mellon Corp now owns 813,288 shares of the company’s stock worth $7,238,000 after purchasing an additional 6,359 shares during the last quarter. Rhumbline Advisers raised its position in Vir Biotechnology by 4.3% during the 2nd quarter. Rhumbline Advisers now owns 238,504 shares of the company’s stock worth $2,123,000 after buying an additional 9,817 shares during the last quarter. Victory Capital Management Inc. lifted its stake in shares of Vir Biotechnology by 41.5% in the 2nd quarter. Victory Capital Management Inc. now owns 65,573 shares of the company’s stock worth $584,000 after acquiring an additional 19,216 shares during the period. Los Angeles Capital Management LLC purchased a new stake in shares of Vir Biotechnology in the second quarter valued at about $119,000. Finally, Quest Partners LLC increased its stake in shares of Vir Biotechnology by 142.1% during the second quarter. Quest Partners LLC now owns 12,695 shares of the company’s stock worth $113,000 after acquiring an additional 7,452 shares during the period. Institutional investors and hedge funds own 65.32% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on the stock. HC Wainwright reiterated a “buy” rating and set a $110.00 target price on shares of Vir Biotechnology in a research note on Wednesday, November 20th. Barclays lowered their price objective on Vir Biotechnology from $28.00 to $26.00 and set an “overweight” rating for the company in a research report on Monday, November 4th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $19.00 price target on shares of Vir Biotechnology in a report on Wednesday, November 20th. Two equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $36.40.

About Vir Biotechnology

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).